Plaque Psoriasis

In recent years, researchers and advocates have vocalized increasing psychological support for patients with psoriasis.

A consensus was reached on nearly all proposals in the eDelphi study, which members said could be used to establish a clear dosing regimen for methotrexate.

An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.

Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.

The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

IL-17 inhibitors were also associated with higher persistence than IL-12 and IL-23 inhibitors for psoriatic arthritis, though no difference was observed for psoriasis.

Dr Jerry Bagel looks to the future of moderate-to-severe plaque psoriasis management.

Investigators note that the histopathologic diagnosis of inflammatory skin disorders can prove challenging, with psoriasis being particularly heterogeneous and dynamic.

Side effects of the vaccines occurred at a lower incidence in the current study.

Patients with psoriasis slept 1 hour less than control subjects, and associations with anxiety and depression were observed.

Jerry Bagel, MD, MS, explains clinical trial data on the investigational anti-IL17A/F monoclonal antibody bimekizumab.

An overview of the novel selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib for the management of plaque psoriasis.

Dr Jerry Bagel describes the unmet needs of plaque psoriasis management.

An expert dermatologist details the effect of the COVID-19 pandemic and other comorbidities on treatment selection for plaque psoriasis.

Though the pathogenesis of psoriasis remains vague, recent studies hypothesized that oxidative stress could be involved in the development and perpetuation of psoriasis.

The safety syringe and auto-injector provide patients with psoriasis with 2 options for the self-administration of bimekizumab.

Jerry Bagel, MD, MS, discuss new targets, treatment goals, and utilizing shared decision making when treating patients with plaque psoriasis.

Jerry Bagel, MD, MS, provides an overview of potential challenges in managing plaque psoriasis and assess to biologics utilized in plaque psoriasis.

Previous research indicated that the worsening of different inflammatory cutaneous diseases had been associated with exposure to air pollution.

Dr Lebwohl concludes by giving advice to community physicians and dermatologist on what they can do to improve treating patients with plaque psoriasis.

The panel ponders how they will incorporate the discussed new agents into their plaque psoriasis treatment processes.

The panel each list challenges and unmet needs faced when managing the treatment of plaque psoriasis.